

REMARKS


In response to the Restriction Requirement dated September 10, 2003 in the U.S. application serial no. 09/929,808 filed August 14, 2001, Applicants withdrew claims 30-41 from the application and hereby pursue their prosecution in the present divisional application.

The present divisional application is directed to a pharmaceutical formulation comprising a new and non-obvious crystalline form of risperidone (i.e., risperidone form B).

Applicants believe that the pending claims are free of prior art and patentable and allowance of these claims is respectfully requested. The Examiner can reach undersigned at (212) 908-6018 when this application is taken up for further action.

Respectfully submitted,
KENYON & KENYON

Date: September 23, 2003

By: 
Siu K. Lo
Reg. No. 46,877

KENYON & KENYON
One Broadway
New York, NY 10004
(212) 908-6018